The invention provides compounds of Formula (I) and pharmaceutical compositionsthereof, which are useful as protein kinase inhibitors, as well as methods forusing such compounds to treat, ameliorate or prevent a condition associatedwith abnormal or deregulated kinase activity. In some embodiments, the inventionprovides methods for using such compounds to treat, ameliorate or prevent diseasesor disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ,CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB,FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, Fms, KDR, c-raf or b-rafkinases.
